Background
The National Cancer Institute Surveillance Research Program (NCI-SRP) has developed a new quality control tool allowing Surveillance, Epidemiology, and End Results (SEER) registry managers to monitor their registry data quality. The Median/Multiple Outlier Testing Method (MMOT) is a benchmarking tool for identifying outliers using multiple hypothesis testing based on the median of the statistic of interest (e.g., proportion unknown). The goal of this method is to identify any outlier datapoint from one SEER registry for a given diagnosis year. This will allow registry managers to investigate issues in data collection, coding, or registry operations beyond characteristics attributable to the underlying patient population.
The Median/Multiple Outlier Testing Method (MMOT)
- Define the population of interest e.g., primary site, diagnosis years
- Calculate the statistic of interest e.g., proportion unknown for summary stage
- Multiple hypothesis testing defines the boundaries, identifying outliers based on the median
- If a registry for a given year falls above the upper boundary then the statistic of interest is higher when compared to the other registries
- Similarly, if a registry for a given year falls below the lower boundary the statistic of interest is lower when compared to the other registries
Data Quality Monitoring Plan
Currently, SEER routinely evaluates the following data items from the most recent November submission using this MMOT tool. However, benchmarking analyses are not limited to these data items.
Data Item | Schema | SSDI Recode # |
---|---|---|
Breslow Tumor Thickness | Melanoma, Skin | 3817 R |
Estrogen Receptor Summary | Breast | 3827 R |
Progesterone Receptor Summary | Breast | 3915 R |
HER2 Overall Summary | Breast | 3855 R |
Gleason Score Clinical | Prostate | 3840 R |
Gleason Score Pathological | Prostate | 3841 R |
Gleason Patterns Clinical | Prostate | 3838 R |
Gleason Patterns Pathological | Prostate | 3839 R |
Prostate Specific Antigen (PSA) Lab Value | Prostate | 3920 R |
KRAS | Colorectal | 3866 R |
Results are posted on the QIE portal with registries deidentified as well as emailed to registry managers. A registry identification number will be emailed to each registry manager.
Defining Proportion Unknown and Aggressive
Proportions were calculated using the Site-Specific Data Item (SSDI) recode definitions to examine their distribution over time. Below is a table that briefly describes how proportions unknown and aggressive are calculated. For more detailed information on the SSDI recode, please refer to the SSDI recode definitions available on the Site-Specific Data Item Recodes page. Selection criteria for each data element that were analyzed using this tool are provided with the results.
Data Item | Schema | SSDI Recode # | Proportion Unknown: Numerator/ Denominator |
Proportion Aggressive*: Numerator/ Denominator |
---|---|---|---|---|
Breslow Thickness | Melanoma, Skin | 3817 R | XX.9/ 0.0-9.7, XX.0, XX.9 | 4.0-9.79, XX.0/ 0.0-9.79, XX.0 |
Estrogen Receptor Summary | Breast | 3827 R | 7, 9/ 0, 1, 7, 9 | 0/ 0, 1 |
Progesterone Receptor Summary | Breast | 3915 R | 7, 9/ 0, 1, 7, 9 | 0/ 0, 1 |
HER2 Overall Summary | Breast | 3855 R | 7, 9/ 0, 1, 7, 9 | 1/ 0, 1 |
Gleason's Score Clinical | Prostate | 3840 R | X9/ 02-10, X7, X9 | 09,10/ 02-10, X7 |
Gleason's Score Pathological | Prostate | 3841 R | X9/ 02-10, X7, X9 | 09,10/ 02-10, X7 |
Gleason Patterns Clinical | Prostate | 3838R | 19, 29, 39, 49, 59, X6, X9/11-59, X6, X7, X9 | 45, 54, 55/11-15, 21-25, 31-34, 41-45, 51-55, X7 |
Gleason Patterns Pathological | Prostate | 3839R | 19, 29, 39, 49, 59, X6, X9/11-59, X6, X7, X9 | 45, 54, 55/11-15, 21-25, 31-34, 41-45, 51-55, X7 |
Prostate Specific Antigen (PSA) Lab Value | Prostate | 3920 R | XXX.2, XXX.3, XXX.7, XXX.9/ 0.1-97.9, XXX.0, XXX.9 | 20.0-97.9, XXX.0/ 0.1-97.9, XXX.0 |
KRAS | Colorectal | 3866 R | 7, 9/ 0, 5, 7, 9 | 5/ 0, 5 |
*Cases that were coded N/A or Test ordered, results not in chart are removed. |
